Reuters UK |
AstraZeneca builds pipeline with $232 million Synairgen asthma deal
Fox Business AstraZeneca has struck a deal worth up to $232 million in milestone payments to acquire rights to a drug from Synairgen for treating respiratory tract viral infections in patients with severe asthma. Britain's second-biggest drugmaker – subject of a … AstraZeneca extends global shopping spree with $232M asthma drug deal Synairgen breathes easier with $225M from Astrazeneca for its asthma drug |
View full post on asthma – Google News